Skip to content

HPV Integration Testing for Human Papillomavirus-Positive Women

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02576262
Enrollment
1200
Registered
2015-10-15
Start date
2015-09-30
Completion date
2020-09-30
Last updated
2017-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer, Cervical Intraepithelial Neoplasia

Brief summary

Papanicolaou (Pap) triage, with high specificity, has been recommended for primary Human papillomavirus (HPV) testing but is flawed by poor sensitivity and cytologist dependence. the investigators evaluated the potential role of HPV Integration detection in cervical exfoliated cells in HPV-positive women from a clinic-based population.

Interventions

Sponsors

Huazhong University of Science and Technology
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

Women aged 30-65 years old visiting the gynecologic clinic of hospital

Exclusion criteria

1. Not providing informed consent 2. previously confirmed CIN, cervical cancer, or other malignancies 3. previous therapeutic procedure to cervix 4. pregnancy

Design outcomes

Primary

MeasureTime frame
Sensitivity and Specificity of the HPV integration screening test with comparison to HPV testing or TCT14 Months

Countries

China

Contacts

Primary ContactDanhui Weng, MD, PhD
weng.dh@gmail.com+862783662681

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026